Multi-index joint detection kit for heart failure risk assessment

Abstract

The utility model discloses a multi-index joint detection kit for heart failure risk assessment, which comprises a shell and a detection card, and the detection card comprises a bottom plate, a sample pad, a combination pad, a detection pad and a sample absorption pad; the multiple indexes comprise three indexes including peptin, cardiac myosin binding protein C and adrenal medullary middle segment peptide; an antibody coating marked by a fluorescent substance is arranged on the combination pad, and an antibody in the antibody coating is a specific detection antibody aiming at three indexes; three parallel and spaced detection lines and a quality control line are arranged on the detection pad, the three detection lines are respectively coated with specific capture antibodies in one-to-one correspondence with three indexes of peptin, cardiac myosin binding protein C and adrenal medullary midsection peptide, and the quality control line is coated with haptens or antibodies capable of being combined with the specific detection antibodies. According to the utility model, three indexes are jointly detected, the detection sensitivity is high, the detection range is wide, and the accuracy and the specificity of early risk assessment of heart failure can be improved.

Description

Technical Field

[0001] The utility model relates to the technical field of biotechnology diagnosis, and in particular to a multi-index combined detection kit for heart failure risk assessment. Background Art

[0002] Heart failure (HF) occurs when the heart's ability to pump blood is insufficient to meet the body's demands, leading to slowed blood flow, blood pooling in the veins and lungs (congestion), and / or other changes that may further weaken heart function or stiffen the heart. Common causes include myocardial infarction, cardiomyopathy, and myocarditis. HF can be categorized as left ventricular failure, right ventricular failure, and total heart failure, depending on the location of the lesion.

[0003] According to the recommendations of the "Expert Consensus on Biomarkers for Cardiovascular Disease Risk Assessment in Physical Examination Populations," copeptin, cardiac myosin-binding protein C (cMyBP-C), and mid-adrenal medullary peptide (MR-proADM) are recommended as cardiac-specific biomarkers in addition to conventional methods such as chest X-ray, electrocardiogram (ECG), and echocardiography to facilitate early screening, prevention, and treatment decisions. Furthermore, according to the recommendations of the "Chinese Expert Consensus on Heart Failure Biomarkers," MR-proADM plays an important role in assessing the short-term prognosis of acute heart failure. Studies have shown that MR-proADM has a stronger predictive effect on 90-day mortality in patients with acute heart failure than BNP or cTn. Approximately one-third of patients with acute heart failure stratified as high-risk by BNP and cTn were reclassified as low-risk after MR-proADM measurement, and its predictive ability was even more accurate.

[0004] Copeptin, a 39-amino acid glycopeptide homologous to arginine vasopressin (AVP), is a C-terminal partial peptide fragment of pro-arginine vasopressin. AVP, also known as vasopressin, and copeptin, as a partially active fragment, exhibits similar changes to AVP and is more stable in vivo, offering advantages such as ease of storage and detection. Recent studies have suggested that copeptin may serve as a new biomarker for detecting coronary artery disease and heart failure. Serum copeptin levels in patients with heart failure are significantly higher than in healthy subjects, and levels increase significantly with increasing heart failure severity. Copeptin levels are closely correlated with echocardiographic parameters and can serve as an effective indicator for clinical assessment of disease severity. Clinical studies have shown that, in the early stages of heart failure (0-4 hours before onset), copeptin levels are more significantly abnormal and more sensitive than troponin, leading to a significant association between copeptin and heart failure.

[0005] Cardiac myosin-binding protein C (cMyBP-C), located between actin and myosin, regulates the contraction and relaxation of cardiomyocytes. With a molecular weight of 140 kD, its N-terminal C0-C2 fragment (molecular weight approximately 40 kD) is the dominant regulator of cardiac physiological function, associated with both contraction and relaxation. It plays a crucial role in maintaining sarcomere structural stability and regulating myocardial contraction. The severity of heart failure (HF) is determined by the degree of systolic and diastolic dysfunction, so cMyBP-C levels may reflect the progression and prognosis of heart failure. Researchers have also examined plasma cMyBP-C levels in infants and young children with heart failure due to acquired or congenital heart disease and found significantly elevated levels.

[0006] Adrenomedullin (ADM) is a 52-amino acid peptide that causes potent vasodilation and hypotension, increases cardiac output, and induces diuresis and natriuresis. MR-proADM, a stable peptide fragment of ADM, is produced by ADM translation and processing, and its levels are remarkably stable, with secretion levels comparable to ADM. Studies have shown that elevated serum MR-proADM levels are associated with future cardiovascular events in patients with coronary artery disease, suggesting potential diagnostic and assessment indicators for heart failure (HF). MR-proADM maintains endothelial integrity and regulates vasodilation. Increased MR-proADM levels directly affect vascular tone, causing vasodilation, lowering blood pressure, and increasing blood flow.

[0007] A single marker is not suitable for use in heart failure risk assessment. Only by using multiple markers can the safety of various parts of the heart be detected more sensitively over a wider range.

[0008] Fluorescence immunochromatography is a novel membrane-based detection technology based on antigen-antibody specific immune reactions. It uses a nitrocellulose strip containing a test line (coated antibody or antigen) and a control line (secondary antibody) as the stationary phase, a test solution as the mobile phase, and a fluorescently labeled antibody or antigen fixed to a conjugate pad. Capillary action moves the analyte along the strip, with specific binding occurring at the test line and nonspecific binding occurring at the control line. This method has the advantages of rapid operation, high sensitivity, and good accuracy, and is widely used.

[0009] Therefore, it is necessary to provide a multi-index detection reagent card based on fluorescent immunochromatography technology to improve the accuracy and specificity of early risk assessment of heart failure, so as to solve the defects of existing detection. Utility Model Content

[0010] In order to solve the above technical problems, the purpose of the present utility model is to provide a multi-indicator combined detection kit for heart failure risk assessment, the detection indicators of which include copeptin, cardiac myosin binding protein C (cMyBP-C) and mid-adrenal medullary peptide (MR-proADM). The combined detection of the three indicators has high detection sensitivity and a wide detection range, which can improve the accuracy and specificity of early risk assessment of heart failure.

[0011] In order to achieve the above technical objectives and the above technical effects, the present invention is implemented through the following technical solutions:

[0012] A multi-index combined detection kit for heart failure risk assessment comprises a housing and a detection card installed in the housing, the detection card comprising a base plate and a sample pad, a conjugation pad, a detection pad and a sample suction pad sequentially and interlacedly arranged on the base plate, the multi-index comprising three indicators: copeptin, cardiac myosin binding protein C and adrenal medullary mid-segment peptide; the conjugation pad is provided with an antibody coating labeled with a fluorescent substance, the antibodies in the antibody coating being specific detection antibodies for the three indicators; the detection pad is provided with three parallel and spaced detection lines and a quality control line, the three detection lines are respectively coated with specific capture antibodies corresponding to the three indicators: copeptin, cardiac myosin binding protein C and adrenal medullary mid-segment peptide, and the quality control line is coated with a hapten or antibody capable of binding to the specific detection antibody.

[0013] Furthermore, the shell includes an upper cover and a lower cover, and the upper cover and the lower cover are also provided with an intermediate base. The upper cover and the intermediate base enclose an upper fixed space, and the lower cover and the intermediate base enclose a lower fixed space; a detection card is installed in each of the upper fixed space and the lower fixed space.

[0014] Furthermore, the housing is provided with a first liquid inlet trough, a second liquid inlet trough and an observation window. The first liquid inlet trough and the second liquid inlet trough are arranged above the sample pad, and the observation window is arranged above the three detection lines and one quality control line.

[0015] Furthermore, the upper cover and the middle base, as well as the lower cover and the middle base, are both positionally connected and docked via a position-limiting structure.

[0016] Furthermore, the limiting structure is an interlocking structure, which is formed by interlocking two interlocking structural members; one of the interlocking structural members is arranged on the middle base, and the other interlocking structural member is arranged at the interlocking position of the upper cover and the lower cover.

[0017] Furthermore, a front limit frame and a rear limit frame are provided on the intermediate base, and the detection card is limited to be located between the front limit frame and the rear limit frame.

[0018] Furthermore, the middle base is provided with a pad and a slope, and the detection card is set on the pad and the slope. The height of the slope gradually decreases along the length direction of the middle base. The position of the pad is close to the sample pad, and the lowest end of the slope is close to the sample suction pad.

[0019] Furthermore, the intermediate base is provided with a liquid storage tank close to the sample suction pad.

[0020] Furthermore, the detection card also includes a blood filter pad, and the blood filter pad, sample pad, binding pad, detection pad, and sample suction pad are sequentially overlapped on the bottom plate.

[0021] Furthermore, the sample pad and the conjugation pad are glass fiber pads or non-woven fabric pads, the detection pad is made of nitrocellulose membrane, the sample absorption pad is made of absorbent filter paper, and the bottom plate is a PVC board.

[0022] Beneficial effects of the utility model:

[0023] This utility model can simply, intuitively, and quickly assess the risk of the onset and progression of heart failure by simultaneously detecting changes in serum and whole blood levels of copeptin, cardiac myosin-binding protein C (cMyBP C), and MR-proADM. This utility model has high sensitivity, high throughput, fast sample processing, and a wide detection range, improving the accuracy and specificity of early risk assessments for heart failure.

[0024] The utility model utilizes two separate liquid inlet tanks and a double-sided detection card to reduce cross-contamination between different samples or reagents and improve the accuracy of the test results. The double liquid inlet tank can better control the contact time and ratio between the sample and the buffer solution, which helps to improve the efficiency and purity of the separation, while allowing the experimenter to flexibly adjust different buffer solutions to optimize the conditions during the experiment. The design of the double-sided reagent card is more suitable for automated operation and can be more easily integrated into an automated detection platform. Furthermore, by integrating multiple detection units on a single detection kit, the use of reagents and consumables can be reduced, thereby reducing the cost of detection. The simple design and intuitive operation process of the double-sided reagent card can also improve the user experience and reduce the possibility of erroneous operation. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 Schematic diagram of the overall structure of the test kit of the present utility model.

[0026] Figure 2 It is a schematic diagram of the disassembly structure (including the cover) of the test kit of the present invention.

[0027] Figure 3It is a schematic diagram of the exploded structure of the detection card in the present utility model.

[0028] Figure 4 It is a schematic diagram of the overall structure of the detection card in the utility model.

[0029] In the figure, 1: outer shell, 101: upper cover, 102: lower cover, 103: observation window, 104: first liquid inlet tank, 105: second liquid inlet tank; 2: intermediate base, 201: front limit frame, 202: rear limit frame, 203: pad, 204: slope, 205: liquid storage tank, 2051: liquid storage dam; 3: limit tube; 4: limit column; 5: test card, 501: bottom plate, 502: blood filter pad, 503: sample pad, 504: binding pad, 505: test pad, 506: sample suction pad. DETAILED DESCRIPTION

[0030] The preferred embodiments of the present invention are described in detail below in conjunction with the accompanying drawings so that the advantages and features of the present invention can be more easily understood by those skilled in the art, thereby making a clearer and more precise definition of the protection scope of the present invention.

[0031] In the description of the present invention, it should be understood that the terms "front", "rear", "left", "right", "up", "down", etc., indicating directions or positional relationships, are based on the directions or positional relationships shown in the accompanying drawings, and are only for the convenience of describing the present invention and simplifying the description, rather than indicating or implying that the device or element referred to must have a specific direction, be constructed and operated in a specific direction, and therefore cannot be understood as a limitation on the present invention.

[0032] like Figures 1 to 4A multi-indicator combined detection kit for heart failure risk assessment is shown, comprising a housing 1 and a detection card 5 installed in the housing 1. The detection card 5 includes a base plate 501 and a sample pad 503, a conjugation pad 504, a detection pad 505, and a sample suction pad 506, which are sequentially and interlaced on the base plate 501. The multi-indicator includes three indicators: copeptin, cardiac myosin binding protein C, and adrenal medullary mid-segment peptide; the conjugation pad 504 is provided with an antibody coating labeled with a fluorescent substance, and the antibodies in the antibody coating are specific detection antibodies for the three indicators; the detection pad 505 is provided with three parallel and spaced detection lines (T1, T2, T3) and a quality control line C, the three detection lines and the quality control line being parallel to each other and arranged along the length of the detection pad 505; the quality control line is adjacent to the sample suction pad 506, and the three detection lines are located on the same side of the quality control line. The spacing between two adjacent detection lines is equal to the spacing between a quality control line and the detection line adjacent to the quality control line. The three test lines are coated with specific capture antibodies corresponding to three indicators: copeptin, cardiac myosin binding protein C, and adrenal medullary mid-segment peptide. Specifically, the three test lines are in the form of antibody coatings. The quality control line is coated with a hapten or antibody capable of binding to the specific detection antibody. The antibody coated on the quality control line can be goat anti-mouse IgG, goat anti-chicken IgY, or goat anti-rabbit IgG antibody.

[0033] It should be noted that the fluorescent substance labeling is time-resolved immunoassay microsphere labeling or quantum dot immunoassay microsphere labeling. Fluorescent substance labeling technology is a prior art known to those skilled in the art and will not be described or limited here.

[0034] like Figure 1 and Figure 2 As shown, the shell 1 includes an upper cover 101 and a lower cover 102, and an intermediate base 2 is provided between the upper cover 101 and the lower cover 102. The upper cover 101 and the intermediate base 2 enclose an upper fixed space, and the lower cover 102 and the intermediate base 2 enclose a lower fixed space; a detection card 5 is respectively installed in the upper fixed space and the lower fixed space.

[0035] In order to guide the test sample to the test card 5, two liquid inlet grooves (funnel-shaped through holes) are provided on the upper cover 101 and the lower cover 102 of the housing 1 corresponding to the sample pad 503, namely the first liquid inlet groove 104 and the second liquid inlet groove 105, one of which is used to add the sample and the other is used to add the buffer solution. In order to facilitate the observation of the test results on the test card 5 more conveniently during use, an observation window 103 is provided on the upper cover 101 and the lower cover 102 of the housing 1 corresponding to the three test lines and the quality control line. The area of ​​the positive projection of the observation window 103 on the test pad 505 should be larger than the size of the area formed by the three test lines, the quality control line and the intervals between the four, so that observation is clearer and more direct.

[0036] By adopting the above technical solution, the kit can increase detection throughput and integrate multiple detection units into a single kit, reducing the use of reagents and consumables, thereby lowering detection costs. In addition, the dual inlet tank can better control the contact time and ratio between sample and buffer, helping to improve separation efficiency and purity, while also allowing experimenters to flexibly adjust different buffers to optimize conditions during the experiment.

[0037] The upper cover 101 and the intermediate base 2, as well as the lower cover 102 and the intermediate base 2, are both positioned and docked via a limiting structure. The limiting structure is preferably a plug-in structure, which is formed by plugging two plug-in components; one plug-in component is provided on the intermediate base, and the other plug-in component is provided at the plug-in position of the upper cover and the lower cover. For example, one plug-in component is a limiting tube 3, and the other plug-in component is a limiting column 4; Figure 2 As shown, the upper cover 101 and the lower cover 102 can be provided with a limit tube 3, and the corresponding position of the intermediate base 2 can be provided with a limit column 4. There is no special limit on the number of the limit columns 4 and the limit tube 3. For example, Figure 2 Four shown.

[0038] The intermediate base 2 is provided with a front limit frame 201 and a rear limit frame 202 , and the detection card 5 is limited between the front limit frame 201 and the rear limit frame 202 .

[0039] By cooperating with the limiting structure, the front limiting frame and the rear limiting frame, the upper cover 101, the lower cover 102, the middle base 2 and the detection card 5 therein can be formed into an integrated structure.

[0040] The intermediate base 2 is also provided with a spacer 203 and a slope 204. The test card 5 is placed on the spacer 203 and the slope 204. The height of the slope 204 gradually decreases along the length of the intermediate base 2. The spacer 203 is located near the sample pad 503, and the lowest end of the slope 204 is located near the sample suction pad 506. The intermediate base 2 is also provided with a liquid reservoir 205 near the sample suction pad 506. The liquid reservoir 205 is enclosed by a liquid reservoir dam 2051.

[0041] By adopting the above technical solution, the sample can slide under gravity based on capillary action, thereby accelerating the flow of the sample, improving the efficiency of the reaction, ensuring a more complete reaction, and improving the accuracy of the test results. Furthermore, the tilted placement of the test card can prevent sample backflow. At the same time, when the volume of the added liquid sample exceeds the amount required for the test, the excess liquid sample is gradually chromatographed onto the sample pad 506, and the excess liquid flows into the liquid reservoir 205. The liquid reservoir dam 2051 blocks the liquid sample within the liquid reservoir 205, preventing it from flowing into the area where the test pad is located, thereby preventing the excess liquid sample from causing a flood, thereby improving the success rate and accuracy of the test results.

[0042] The test card 5 further comprises a blood filter pad 502. The blood filter pad 502, sample pad 503, conjugation pad 504, test pad 505 and sample suction pad 506 are sequentially overlapped on the bottom plate 501. The provision of the blood filter pad can make the test card more suitable for whole blood sample testing.

[0043] As for the materials of each part of the detection card, the sample pad 503 and the conjugation pad 504 are glass fiber pads or non-woven fabric pads, the detection pad 505 is made of nitrocellulose membrane, the sample absorption pad 506 is made of absorbent filter paper, and the bottom plate 501 is a PVC board.

[0044] The utility model utilizes the fluorescence characteristics of time-resolved immune microspheres and quantum dot immune microspheres and adopts the fluorescence immunochromatography method to simultaneously perform rapid and sensitive joint detection of copeptin, cMyBP-C, and MR-proADM proteins. It is simple to operate and has a wide range of application environments. The multi-indicator joint diagnosis helps to improve detection accuracy and sensitivity. At the same time, the utility model can increase detection throughput, reduce the use of reagents and consumables, and reduce detection costs, and can be used for risk assessment of heart failure.

[0045] Example 1

[0046] like Figures 1 to 4As shown, the multi-index combined detection kit for heart failure risk assessment of this embodiment 1 includes a shell 1, the shell 1 includes an upper cover 101 and a lower cover 102, and an intermediate base 2 is also provided in the shell 1. The upper cover 101 and the intermediate base 2 enclose an upper fixed space, and the lower cover 102 and the intermediate base 2 enclose a lower fixed space; a detection card 5 is respectively installed in the upper fixed space and the lower fixed space. The test card 5 includes a base plate 501 and a blood filter pad 502, a sample pad 503, a conjugation pad 504, a test pad 505, and a sample suction pad 506, which are arranged in an interlaced manner on the base plate 501. The multiple indicators include three indicators: copeptin, cardiac myosin binding protein C, and adrenal medullary mid-segment peptide; the conjugation pad 504 is provided with an antibody coating labeled with time-resolved immunosorbent microspheres, and the antibodies in the antibody coating are specific detection antibodies for the three indicators; the test pad 505 is provided with three parallel and spaced test lines (T1, T2, T3) and a quality control line C, which are parallel to each other and arranged along the length of the test pad 505; the quality control line is adjacent to the sample suction pad 506, and the three test lines are located on the same side of the quality control line. The spacing between two adjacent test lines is equal to the spacing between the quality control line and the test line adjacent to the quality control line. The three test lines are coated with specific capture antibodies corresponding to three indicators: copeptin, cardiac myosin binding protein C, and adrenal medullary mid-segment peptide. Specifically, the three test lines are in the form of antibody coatings. The quality control line is coated with a hapten or antibody that can bind to the specific detection antibodies.

[0047] Two liquid inlet slots, a first liquid inlet slot 104 and a second liquid inlet slot 105, are provided on both the upper cover 101 and the lower cover 102 of the housing 1, corresponding to the sample pad 503. One of the liquid inlet slots is used to add the sample, and the other is used to add the buffer. Observation windows 103 are provided on both the upper cover 101 and the lower cover 102 of the housing 1, corresponding to the three test lines and the one quality control line.

[0048] The upper cover 101 and the intermediate base 2 as well as the lower cover 102 and the intermediate base 2 are both positioned and docked via a positioning structure. The positioning structure includes a positioning tube 3 and a positioning column 4; Figure 2 As shown, four limiting tubes 3 are respectively provided on the upper cover 101 and the lower cover 102, and four limiting posts 4 are respectively provided at corresponding positions on the middle base 2. The limiting tubes 3 and the limiting posts 4 are plugged and fixed.

[0049] The intermediate base 2 is provided with a front limit frame 201 and a rear limit frame 202 , and the detection card 5 is limited between the front limit frame 201 and the rear limit frame 202 .

[0050] The intermediate base 2 is also provided with a spacer 203 and a slope 204. The test card 5 is placed on the spacer 203 and the slope 204. The height of the slope 204 gradually decreases along the length of the intermediate base 2. The spacer 203 is located near the sample pad 503, and the lowest end of the slope 204 is located near the sample suction pad 506. The intermediate base 2 is also provided with a liquid reservoir 205 near the sample suction pad 506. The liquid reservoir 205 is enclosed by a liquid reservoir dam 2051.

[0051] In this embodiment, the sample pad 503 and the conjugation pad 504 are glass fiber pads or non-woven fabric pads, the detection pad 505 is made of nitrocellulose membrane, the sample absorption pad 506 is made of absorbent filter paper, and the bottom plate 501 is a PVC board.

[0052] Example 2

[0053] The detection card of Example 2 is different from that of Example 1 in that the fluorescent marker is replaced with quantum dot immunomicrospheres, and the rest is the same as that of Example 1.

[0054] The method of using the kit of the utility model embodiment is as follows:

[0055] After the user drops the diluent and the sample to be tested (serum, whole blood) into the first liquid inlet 104 and the second liquid inlet 105 of the test card 5 respectively, the antigen in the sample combines with the fluorescently labeled copeptin, cMyBP-C, and MR-proADM protein monoclonal antibodies to form a reaction complex. Under the action of chromatography, the reaction complex moves forward along the detection pad made of nitrocellulose membrane and moves to the detection lines T1, T2, and T3. The reaction complex is captured to form a final reaction complex; the corresponding monoclonal antibody at the quality control line C captures the formed complex.

[0056] During the test, if no band appears at the quality control line C, it means that the test card 5 is invalid; if a band appears at the quality control line C, but no band appears at the test lines T1, T2, and T3, it means that the sample to be tested does not contain antigens and is negative; if a band appears at one or some of the test lines T1, T2, and T3, it means that the corresponding antigens are present in the sample to be tested and is positive.

[0057] For quantitative detection, a dedicated fluorescent immunoassay analyzer is used to detect the quality control line C and the detection lines T1, T2, and T3 according to a pre-set standard curve.

[0058] If no fluorescent signal is detected on the quality control line C, the experiment fails and needs to be retested.

[0059] It will be apparent to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above, and that the present invention can be implemented in other specific forms without departing from the spirit or essential features of the present invention. Therefore, the embodiments should be considered in all respects as illustrative and non-restrictive, and the scope of the present invention is defined by the appended claims rather than the foregoing description, and it is intended that all variations that come within the meaning and range of equivalents of the claims be embraced within the present invention.

[0060] In addition, it should be understood that although this specification is described in terms of implementation methods, not every implementation method contains only one independent technical solution. This narrative method of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment can also be appropriately combined to form other implementation methods that can be understood by those skilled in the art.

Claims

1. A multi-indicator combined detection kit for heart failure risk assessment, comprising a housing and a detection card installed in the housing, wherein the detection card comprises a base plate and a sample pad, a conjugation pad, a detection pad, and a sample suction pad sequentially and alternately arranged on the base plate, characterized in that: The multiple indicators include three indicators: copeptin, cardiac myosin binding protein C, and adrenal medullary mid-segment peptide; the binding pad is provided with an antibody coating labeled with a fluorescent substance, and the antibodies in the antibody coating are specific detection antibodies for the three indicators; the detection pad is provided with three parallel and spaced detection lines and a quality control line, the three detection lines are respectively coated with specific capture antibodies corresponding to the three indicators: copeptin, cardiac myosin binding protein C, and adrenal medullary mid-segment peptide, and the quality control line is coated with a hapten or antibody capable of binding to the specific detection antibody; The shell includes an upper cover and a lower cover, and the upper cover and the lower cover are also provided with an intermediate base. The upper cover and the intermediate base enclose an upper fixed space, and the lower cover and the intermediate base enclose a lower fixed space; a detection card is installed in each of the upper fixed space and the lower fixed space.

2. A multi-index combined detection kit for heart failure risk assessment according to claim 1, characterized in that: The housing is provided with a first liquid inlet trough, a second liquid inlet trough and an observation window. The first liquid inlet trough and the second liquid inlet trough are arranged above the sample pad, and the observation window is arranged above the three detection lines and one quality control line.

3. A multi-index combined detection kit for heart failure risk assessment according to claim 1, characterized in that: The upper cover and the middle base, as well as the lower cover and the middle base, are both positionally connected and docked via a position-limiting structure.

4. A multi-index combined detection kit for heart failure risk assessment according to claim 3, characterized in that: The limiting structure is an interlocking structure, which is formed by interlocking two interlocking structural members; one interlocking structural member is arranged on the middle base, and the other interlocking structural member is arranged at the interlocking position of the upper cover and the lower cover.

5. A multi-index combined detection kit for heart failure risk assessment according to claim 1, characterized in that: The middle base is provided with a front limit frame and a rear limit frame, and the detection card is limited to be located between the front limit frame and the rear limit frame.

6. A multi-index combined detection kit for heart failure risk assessment according to claim 1, characterized in that: The middle base is provided with a pad and a slope, and the detection card is set on the pad and the slope. The height of the slope gradually decreases along the length direction of the middle base. The pad is located close to the sample pad, and the lowest end of the slope is close to the sample suction pad.

7. A multi-index combined detection kit for heart failure risk assessment according to claim 1, characterized in that: The middle base is also provided with a liquid storage tank close to the sample suction pad.

8. A multi-index combined detection kit for heart failure risk assessment according to claim 1, characterized in that: The detection card further comprises a blood filter pad, wherein the blood filter pad, sample pad, binding pad, detection pad and sample suction pad are sequentially overlapped on the bottom plate.

9. A multi-index combined detection kit for heart failure risk assessment according to claim 1, characterized in that: The sample pad and the conjugation pad are glass fiber pads or non-woven fabric pads, the detection pad is made of nitrocellulose membrane, the sample absorption pad is made of absorbent filter paper, and the bottom plate is a PVC board.

Images